AB245116

Anti-Flt3 / CD135 抗体 [EPR22232-318]

Anti-Flt3 / CD135 antibody [EPR22232-318]

RabMAb
Recombinant
KO Validated
詳細を見る

Be the first to review this product! Submit a review

(9 Publications)

Knockout Tested Rabbit Recombinant Monoclonal Flt3 / CD135 antibody. Suitable for IP, WB and reacts with Human samples. Cited in 9 publications.

別名を表示する

CD135, FLK2, STK1, FLT3, Receptor-type tyrosine-protein kinase FLT3, FL cytokine receptor, Fetal liver kinase-2, Fms-like tyrosine kinase 3, Stem cell tyrosine kinase 1, FLK-2, FLT-3, STK-1

4 Images

Unknown

Immunoprecipitation - Anti-Flt3 / CD135 antibody [EPR22232-318] (AB245116)

Flt3 / CD135 was immunoprecipitated from 0.35 mg of THP-1 (human monocytic leukemia cell line) whole cell lysate with ab245116 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab245116 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.

Lane 1 : THP-1 whole cell lysate 10 μg (Input).
Lane 2 : ab245116 IP in THP-1 whole cell lysate (+).
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab245116 in THP-1 whole cell lysate (-).

Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 1 minute.

All lanes:

Immunoprecipitation - Anti-Flt3 / CD135 antibody [EPR22232-318] (ab245116)

Predicted band size: 112 kDa

Observed band size: 120 kDa

false

Unknown

Western blot - Anti-Flt3 / CD135 antibody [EPR22232-318] (AB245116)

Blocking and dilution buffer : 5% NFDM/TBST.

The molecular weight observed is consistent with literature (PMID : 12406902, PMID : 28895560).

Negative control : U-937 (PMID : 12406902).

All lanes:

Western blot - Anti-Flt3 / CD135 antibody [EPR22232-318] (ab245116) at 1/1000 dilution

Lane 1:

THP-1 (human monocytic leukemia cell line) whole cell lysate at 20 µg

Lane 2:

U937 (human histiocytic lymphoma cell line) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 112 kDa

Observed band size: 130 kDa,160 kDa

false

Exposure time: 70s

Supplier Data

Western blot - Anti-Flt3 / CD135 antibody [EPR22232-318] (AB245116)

False colour image of Western blot : Anti-Flt3 / CD135 antibody [EPR22232-318] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab245116 was shown to bind specifically to Flt3 / CD135. A band was observed at 130 kDa in wild-type THP-1 cell lysates with no signal observed at this size in FLT3 knockout cell line ab282857 (knockout cell lysate ab283225). The band observed at 60 kDa has not been identified. To generate this image, wild-type and FLT3 knockout THP-1 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

All lanes:

Western blot - Anti-Flt3 / CD135 antibody [EPR22232-318] (ab245116) at 1/1000 dilution

Lane 1:

Wild-type THP-1 cell lysate at 20 µg

Lane 2:

Western blot - Human FLT3 (CD135) knockout THP-1 cell lysate (ab283225) at 20 µg

Secondary

All lanes:

Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution

Predicted band size: 112 kDa

Observed band size: 130 kDa

false

Unknown

Western blot - Anti-Flt3 / CD135 antibody [EPR22232-318] (AB245116)

Blocking and dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-Flt3 / CD135 antibody [EPR22232-318] (ab245116) at 1/1000 dilution

All lanes:

His-tagged human Flt3 / CD135 active protein (aa27-541), 20 ng

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 112 kDa

Observed band size: 120 kDa

false

Exposure time: 6s

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR22232-318

アイソタイプ

IgG

キャリアフリー

交差種

Human

アプリケーション

IP, WB

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

style

left-column

製品の詳細

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

出荷温度及び保存条件

製品の状態

Liquid

精製方法

Affinity purification Protein A

バッファー組成

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

出荷温度

Blue Ice

短期保存期間

1-2 weeks

短期保存温度

+4°C

長期保存温度

-20°C

分注に関する情報

Upon delivery aliquot

保管に関する情報

Avoid freeze / thaw cycle

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Flt3 also known as CD135 or FLT3 tyrosine kinase is a receptor tyrosine kinase that belongs to the class III receptor tyrosine kinase family. It has a molecular weight of approximately 160 kDa. This protein plays an important role in the development of hematopoietic stem and progenitor cells. Flt3 is expressed mainly in early progenitor cells within the bone marrow. Additionally it is present in some populations of mature cells in the peripheral blood and lymphoid organs.

Biological function summary

Flt3 functions as a receptor that is activated by binding to its ligand FLT3 ligand (FLT3L). This interaction stimulates the associated tyrosine kinase activity leading to auto-phosphorylation of Flt3 and subsequent downstream signaling. Flt3 does not form a heterocomplex rather it dimerizes upon ligand binding to initiate signaling cascades. These cascades promote cell proliferation differentiation and survival particularly impacting hematopoiesis and immune responses.

Pathways

Flt3 signaling impacts the internal signaling networks involving the MAPK/ERK and PI3K/AKT pathways both central to cell cycle regulation and apoptosis. Flt3 interacts functionally with proteins such as SHP2 and GRB2 in these pathways aiding signal transduction. The Flt3 receptor also shares functional motifs with KIT and PDGF receptors indicating shared regulatory mechanisms involved in cellular proliferation.

Flt3 mutations especially internal tandem duplications in Flt3/ITD are significant in acute myeloid leukemia (AML) leading to abnormal cell growth and survival. These mutations often co-occur with other genetic anomalies such as NPM1 mutations contributing to the oncogenic process. The abnormal activation of Flt3 kinase activity also has ramifications in myelodysplastic syndromes making it a target for therapeutic intervention with drugs such as anti-FLT3 inhibitors in the treatment regime.

style

left-column

style

left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

ターゲットの情報

Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.

See full target information FLT3

style

left-column

文献 (9)

Recent publications for all applications. Explore the full list and refine your search

Cell communication and signaling : CCS 23:162 PubMed40176110

2025

Decursin induces FLT3-ITD acute myeloid leukemia cell apoptosis by increasing the expression of the ubiquitin-conjugase UBE2L6.

Applications

Unspecified application

Species

Unspecified reactive species

Tianxin Zhang,Yuchen Li,Wenhao Liao,Yu Mou,Xue Zhan,Qiongying Hu,Ziyi Zhao,Daqian Xiong

Journal of Cancer 16:1905-1917 PubMed40092706

2025

Mitoxantrone-liposome Sensitizes Acute Myeloid Leukemia to Gilteritinib Treatment.

Applications

Unspecified application

Species

Unspecified reactive species

Shiyi Yuan,Ying Zhou,Yifei Li,Zhe Chen,Wenrui Xiao,Danqing Jiang,Ping Zhang,Ying Zhang,Fengxia Bai,Jianchuan Deng,Shifeng Lou

Scientific reports 15:327 PubMed39747903

2025

FN1 shapes the behavior of papillary thyroid carcinoma through alternative splicing of EDB region.

Applications

Unspecified application

Species

Unspecified reactive species

Mian Liu,Pei Chen,Bo Wei,Hai-Long Tan,Ya-Xin Zhao,Lei Ai,Ning Li,Ying-Ke Jiang,Jing Lin,Shi-Jin Li,Shi Chang

Cancer cell international 23:302 PubMed38037057

2023

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia.

Applications

Unspecified application

Species

Unspecified reactive species

Xinhua Xiao,Peihong Wang,Weina Zhang,Jiayi Wang,Mansi Cai,Hua Jiang,Yingli Wu,Huizhuang Shan

Biomarker research 11:8 PubMed36691065

2023

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia.

Applications

Unspecified application

Species

Unspecified reactive species

Yvyin Zhang,Peihong Wang,Yang Wang,Yang Shen

Cells 11: PubMed36078163

2022

Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of -Mutated Acute Myeloid Leukemia.

Applications

Unspecified application

Species

Unspecified reactive species

Shuangshuang Wu,Holly Edwards,Deying Wang,Shuang Liu,Xinan Qiao,Jenna Carter,Yue Wang,Jeffrey W Taub,Guan Wang,Yubin Ge

STAR protocols 3:101512 PubMed35779262

2022

RNA interference protocol to silence oncogenic drivers in leukemia cell lines.

Applications

Unspecified application

Species

Unspecified reactive species

Mandy Beyer,Oliver H Krämer

Blood cancer journal 12:5 PubMed35017466

2022

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).

Applications

Unspecified application

Species

Unspecified reactive species

Warren Fiskus,Steffen Boettcher,Naval Daver,Christopher P Mill,Koji Sasaki,Christine E Birdwell,John A Davis,Koichi Takahashi,Tapan M Kadia,Courtney D DiNardo,Qi Jin,Yuan Qi,Xiaoping Su,Gerard M McGeehan,Joseph D Khoury,Benjamin L Ebert,Kapil N Bhalla

Blood cancer journal 11:111 PubMed34099621

2021

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.

Applications

Unspecified application

Species

Unspecified reactive species

Xinan Qiao,Jun Ma,Tristan Knight,Yongwei Su,Holly Edwards,Lisa Polin,Jing Li,Juiwanna Kushner,Sijana H Dzinic,Kathryn White,Jian Wang,Hai Lin,Yue Wang,Liping Wang,Guan Wang,Jeffrey W Taub,Yubin Ge

View all publications

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-Flt3 / CD135 抗体 [EPR22232-318]

Anti-Flt3 / CD135 antibody [EPR22232-318]

Immunoprecipitation - Anti-Flt3 / CD135 antibody [EPR22232-318] (AB245116)

Western blot - Anti-Flt3 / CD135 antibody [EPR22232-318] (AB245116)

Western blot - Anti-Flt3 / CD135 antibody [EPR22232-318] (AB245116)

Western blot - Anti-Flt3 / CD135 antibody [EPR22232-318] (AB245116)

関連する標識済み抗体及び組成の異なる製品 (1)

Key facts

宿主種

クローン性

クローン番号

アイソタイプ

キャリアフリー

交差種

アプリケーション

免疫原

Reactivity data

製品の詳細

出荷温度及び保存条件

製品の状態

精製方法

バッファー組成

出荷温度

短期保存期間

短期保存温度

長期保存温度

分注に関する情報

保管に関する情報

補足情報

Biological function summary

Pathways

製品プロトコール

ターゲットの情報

文献 (9)

代替製品

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

組合せ製品

Assay Kits

Primary Antibodies

Primary Antibodies

Primary Antibodies

Secondary Antibodies

Abcam product promise